Genetron Holdings Limited (“Genetron Health” or the “Company”,
NASDAQ:GTH), a leading precision oncology platform company in China
that specializes in offering molecular profiling tests, early
cancer screening products and companion diagnostics development,
today announced its unaudited financial results for the third
quarter ended September 30, 2020 and provided an update on
recent developments.
Third Quarter 2020 Unaudited Financial
and Recent Operating Highlights
- Recorded total revenue of RMB112.0
million for the third quarter 2020, representing a 37.6% increase
over the same period of 2019.
- Diagnosis and monitoring
revenue increased to RMB101.5 million in the third quarter
2020, representing a 45.0% increase over the same period of
2019.
- Gross margin improved to 62.2% for
the third quarter 2020, compared to 44.2% in the same period of
2019.
- Received U.S. FDA breakthrough
device designation for its blood-based NGS test, HCCscreenTM, for
early detection of hepatocellular carcinoma in September 2020.
- Joined a major R&D project led
by the Ministry of Science and Technology in China for early
screening of lung and digestive system cancers.
- Entered into exclusive global
licensing agreement with ImmuQuad Biotechnologies to develop and
commercialize minimal residual disease (MRD) assays in hematologic
cancer in October 2020.
- Launched clinical trial in China
for companion diagnostic test in development for avapritinib with
its strategic partner CStone Pharmaceuticals.
- Established partnership with dMed
Biopharmaceuticals to pioneer a "one-stop" new drug research and
development service offering and registration services in both
China and the U.S. for biopharmaceutical companies.
- Presented data from 18 studies in
conjunction with its collaborations at ESMO 2020.
“Despite COVID-19 pandemic’s impact in some of
our major markets in the third quarter, we continued to see robust
top-line growth with 37.6% year-over-year increase, representing an
acceleration from the 28.3% year-over-year growth seen in the first
half of 2020. The upward sales momentum was accompanied by
strong margin improvements and SG&A operational efficiencies,
compared to the same period last year,” remarked Mr. Sizhen Wang,
co-founder and CEO of Genetron Health. “Overall, we had an
eventful quarter and made significant progress across all business
lines, and we are very pleased with our operational accomplishments
and financial results.”
“Looking ahead, although the pandemic has
largely remained stable in China in the recent weeks, we remain
vigilant regarding the situation. With that said, we are
particularly encouraged by our IVD (in-vitro diagnostic) and early
screening sales momentum and expect those to be the growth drivers
heading into next year. Our strategic focus going forward will be
to accelerate the development of liquid biopsy-based solutions
across the full-cycle cancer management, particularly in early
screening and MRD. In early screening for liver cancer, we plan to
further ramp up our commercialization initiatives in China, while
advancing the preparations to commence clinical trials in both
China and the US. We are progressing on a case control early
screening study for colorectal cancer as well and expect to report
preliminary data in 2021. Genetron is also working on other MRD
projects in solid tumors with an initial focus on liver and
colorectal cancer. For biopharma services, our pipeline is looking
strong thanks partly to our newly added MRD capability in
hematologic cancer. We are confident that we would become a
prominent player in the liquid biopsy space and are committed to
bringing these innovative products to patients faster,” concluded
Mr. Wang.
Third Quarter 2020 Unaudited Financial
ResultsTotal revenue for the third quarter 2020 increased
by 37.6% to RMB112.0 million (US$16.5 million) from RMB81.3 million
in the same period of 2019.
Diagnosis and monitoring revenue increased
by 45.0% to RMB101.5 million (US$15.0 million) in the third quarter
2020 from RMB70.0 million in the same period of 2019. The
increase was driven by the growth in the revenues generated from
both the provision of LDT services and the sale of IVD
products.
- Revenue generated from the
provision of LDT services increased by 17.9% to RMB71.4 million
(US$10.5 million) during the third quarter 2020 from RMB60.5
million in the same period of 2019. LDT diagnostic tests sold in
the third quarter 2020 totaled approximately 5,900 units,
representing an increase of 5% compared to the number of LDT
diagnostic tests sold in the same period of 2019. The average
selling price also increased compared to the same period in 2019,
attributable to a shift to higher value products such as Genetron
Health’s Onco PanScan™. In the third quarter, sales of LDT services
included sales of our early screening test, HCCscreenTM, in the
form of LDT services, which contributed to a small portion of total
LDT revenue.
- Revenue generated from sale of IVD
products increased by 217.3% to RMB30.1 million (US$4.4 million) in
the third quarter 2020 from RMB9.5 million in the third quarter
2019. The increase was mainly driven by the increase in the number
of assays and sequencing platforms sold in the third quarter 2020,
notably the Genetron S5 instrument and Lung 8 Assay.
Contracted in-hospital
partners
| |
|
|
|
|
| |
2019 |
1Q20 |
2Q20 |
3Q20 |
| IVD In-hospital
partners |
13 |
13 |
18 |
20 |
| |
|
|
|
|
| |
2019 |
1Q20 |
2Q20 |
3Q20 |
| Total in-hospital
partners(1) |
25 |
26 |
35 |
38 |
| Note:(1) The
number of total in-hospital partners include both sales of LDT
services and IVD products. |
Revenue generated from development services
decreased by 7.6% to RMB10.4 million (US$1.5 million) in the third
quarter 2020, from RMB11.3 million in the same period of 2019. The
change mainly resulted from the decrease in sequencing services,
reflecting the adjustment of the Company’s business strategy
towards biopharmaceutical services and in the increased revenue
from biopharmaceutical services recorded in the third quarter
2020.
Despite higher revenue, cost of revenue
decreased by 6.8% to RMB42.3 million (US$6.2 million) for the three
months ended September 30, 2020, compared to RMB45.4 million in the
same period of 2019. These decreases were primarily due to
economies of scale.
Gross profit increased by 93.7% to RMB69.6
million (US$10.3 million) in the third quarter 2020 from RMB35.9
million in the same period of 2019. Gross margin increased to 62.2%
for the third quarter of 2020, compared to 44.2% in the same period
of 2019. Year-over-year gross margin improvements were seen across
all major business lines, mainly attributable to improved scale,
operational optimization, and better product mix.
Operating expenses increased by 7.4% to RMB128.8
million (US$19.0 million) for the three months ended September 30,
2020, from RMB120.0 million in the same period of 2019.
Selling expenses continued to decline,
decreasing by 7.9% to RMB60.6 million (US$8.9 million) in the third
quarter 2020 from RMB65.7 million in the same period of 2019.
Selling expenses as a percentage of revenues decreased to 54.1% in
the third quarter 2020 from 80.8% in the same period of 2019. These
decreases were primarily due to increased sales productivity.
Administrative expenses decreased by 2.9% to
RMB32.4 million (US$4.8 million) in the third quarter 2020 from
RMB33.4 million in the same period of 2019. Administrative expenses
as a percentage of revenues decreased to 29.0% in the third quarter
2020 from 41.1% in the third quarter 2019, reflecting the benefit
of improved operational scale.
Research and development expenses increased by
85.8% to RMB38.6 million (US$5.7 million) in the third quarter 2020
from RMB20.8 million in the same period of 2019. The increase was
driven by continued innovation efforts inclusive of development of
new products and technologies, as well as clinical trial
activities. Research and development expenses as a percentage of
revenues increased to 34.4% in the third quarter of 2020 from 25.5%
in the same period of 2019.
As a result of the above, operating loss
decreased by 29.5% to RMB59.2 million (US$8.7 million) for the
three months ended September 30, 2020, from RMB84.0 million for the
three months ended September 30, 2019.
Finance income increased to RMB12.8 million
(US$1.9 million) in the third quarter 2020 from RMB26,000 in the
same period of 2019. The increase was driven by the foreign
currency exchange gain.
Loss for the period was RMB48.0 million (US$7.1
million) for the three months ended September 30, 2020, compared to
RMB274.1 million for the three months ended September 30, 2019.
Non-IFRS loss for the period, defined as loss
for the period excluding share-based compensation expenses, fair
value change and other loss of financial instruments with preferred
rights, was RMB43.7 million (US$6.4 million) for the three months
ended September 30, 2020, compared to RMB75.4 million for the three
months ended September 30, 2019.
Basic loss per ordinary share was RMB0.11
(US$0.02) for the third quarter of 2020, compared with a basic loss
per ordinary share of RMB2.15 for the same period of 2019.
Excluding share-based compensation expenses, fair value change of
financial instruments with preferred rights and other loss of
financial instruments with preferred rights, non-IFRS basic loss
per ordinary share was RMB0.10 (US$0.01) for the third quarter of
2020, compared with non-IFRS basic loss per ordinary share of
RMB0.59 for the same period of 2019. Diluted loss per ordinary
share is equivalent to basic loss per ordinary share. Each ADS
represents of five ordinary shares, par value US$0.00002 per
share.
Cash, cash equivalents and financial assets at
fair value were RMB1,868.5 million (US$275.2 million) as of
September 30, 2020.
Conference CallA conference
call and webcast to discuss the results will be held at 8:30 a.m.
U.S. Eastern Time on November 9, 2020 (or at 9:30 pm Beijing Time
on November 9, 2020). Interested parties may listen to the
conference call by dialing numbers below:
| United
States: |
+1
845-675-0437 |
| China Domestic: |
400-620-8038 |
| Hong Kong: |
+852-3018-6771 |
| International: |
+65-6713-5090 |
| Conference ID: |
5248398 |
Participants are encouraged to dial into the
call at least 15 minutes in advance due to high call volumes.
The replay will be accessible through December
9, 2020, by dialing the following numbers:
| United
States: |
+1-855-452-5696 |
| International: |
+61-2-8199-0299 |
| Conference ID: |
5248398 |
A simultaneous webcast of the conference call
will be available on the "News and Events" page of the Investors
section of the Company's website. A replay of the webcast will be
available for 30 days following the event. For more information,
please visit ir.genetronhealth.com.
About Genetron Holdings
LimitedGenetron Holdings Limited (“Genetron Health” or the
“Company”) (Nasdaq:GTH) is a leading precision oncology platform
company in China that specializes in cancer molecular profiling and
harnesses advanced technologies in molecular biology and data
science to transform cancer treatment. The Company has developed a
comprehensive oncology portfolio that covers the entire spectrum of
cancer management, addressing needs and challenges from early
screening, diagnosis and treatment recommendations, as well as
continuous disease monitoring and care. Genetron Health also
partners with global biopharmaceutical companies and offers
customized services and products. For more information, please
visit ir.genetronhealth.com.
Safe Harbor Statement This
press release contains forward-looking statements. These statements
are made under the “safe harbor” provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Statements that are not
historical facts, including statements about the Company’s beliefs
and expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties, and a number
of factors could cause actual results to differ materially from
those contained in any forward-looking statement. In some cases,
forward-looking statements can be identified by words or phrases
such as “may”, “will,” “expect,” “anticipate,” “target,” “aim,”
“estimate,” “intend,” “plan,” “believe,” “potential,” “continue,”
“is/are likely to” or other similar expressions. Further
information regarding these and other risks, uncertainties or
factors is included in the Company’s filings with the SEC. All
information provided in this press release is as of the date of
this press release, and the Company does not undertake any duty to
update such information, except as required under applicable
law.
Exchange Rate Information All
translations made in the financial statements or elsewhere in this
press release made from RMB into United States dollars (“US$”) are
solely for convenience and calculated at the rate of
US$1.00=RMB6.7896, representing the exchange rate as of September
30, 2020, set forth in the H.10 statistical release of the U.S.
Federal Reserve Board. No representation is made that the RMB
amounts could have been, or could be, converted, realized or
settled into US$ at that rate, or at any other rate, on September
30, 2020.
Non-IFRS Financial Measures The
Company uses non-IFRS loss and non-IFRS loss per ordinary share for
the year/period, which are non-IFRS financial measures, in
evaluating its operating results and for financial and operational
decision-making purposes. The Company believes that non-IFRS loss
and non-IFRS loss per ordinary share help identify underlying
trends in the Company's business that could otherwise be distorted
by the effect of certain expenses that the Company includes in its
loss for the year/period. The Company believes that non-IFRS loss
and non-IFRS loss per ordinary share for the year/period provide
useful information about its results of operations, enhances the
overall understanding of its past performance and future prospects
and allows for greater visibility with respect to key metrics used
by its management in its financial and operational
decision-making.
Non-IFRS loss and non-IFRS loss per ordinary
share for the year/period should not be considered in isolation or
construed as an alternative to operating profit, loss for the
year/period or any other measure of performance or as an indicator
of its operating performance. Investors are encouraged to review
non-IFRS loss and non-IFRS loss per ordinary share for the
year/period and the reconciliation to its most directly comparable
IFRS measures. Non-IFRS loss and non-IFRS loss per ordinary share
for the year/period presented here may not be comparable to
similarly titled measures presented by other companies. Other
companies may calculate similarly titled measures differently,
limiting their usefulness as comparative measures to the Company's
data. The Company encourages investors and others to review its
financial information in its entirety and not rely on a single
financial measure.
Non-IFRS loss and non-IFRS loss per ordinary
share for the year/period represent loss for the year/period
excluding share-based compensation expenses, fair value change of
financial instruments with preferred rights and other loss of
financial instruments with preferred rights (if applicable).
Please see the “Unaudited Non-IFRS Financial
Measure” included in this press release for a full reconciliation
of non-IFRS loss for the year/period to loss for the year/period
and non-IFRS loss per ordinary share for the year/period to loss
per ordinary share for the year/period.
Investor Relations
ContactUS:Hoki LukHead of Investor RelationsEmail:
hoki.luk@genetronhealth.comPhone: +1 (408) 891-9255
Stephanie CarringtonWestwicke, an ICR CompanyEmail:
Stephanie.Carrington@westwicke.comOffice: +1 (646) 277-1282
Asia:Bill ZimaICR, Inc.Email:
bill.zima@icrinc.comir@genetronhealth.com
Media Relations ContactEdmond
LococoICREdmond.Lococo@icrinc.comMobile: +86
138-1079-1408pr@genetronhealth.com
GENETRON HOLDINGS LIMITEDUNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF LOSS
| |
For the
three months ended |
|
For the nine months ended |
| |
|
| |
September30,
2019 |
September 30, 2020 |
|
September30,
2019 |
September
30, 2020 |
| |
RMB’000 |
RMB’000 |
US$’000 |
|
RMB’000 |
RMB’000 |
US$’000 |
|
Revenue |
81,344 |
|
|
111,963 |
|
|
16,490 |
|
|
220,485 |
|
|
290,541 |
|
|
42,792 |
|
| Cost of revenue |
(45,398 |
) |
|
(42,331 |
) |
|
(6,235 |
) |
|
(121,315 |
) |
|
(114,448 |
) |
|
(16,856 |
) |
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| Gross profit |
35,946 |
|
|
69,632 |
|
|
10,255 |
|
|
99,170 |
|
|
176,093 |
|
|
25,936 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| Selling expenses |
(65,716 |
) |
|
(60,558 |
) |
|
(8,919 |
) |
|
(184,549 |
) |
|
(175,000 |
) |
|
(25,775 |
) |
| Administrative expenses |
(33,416 |
) |
|
(32,440 |
) |
|
(4,778 |
) |
|
(88,471 |
) |
|
(81,969 |
) |
|
(12,073 |
) |
| Research and development expenses |
(20,752 |
) |
|
(38,556 |
) |
|
(5,679 |
) |
|
(59,336 |
) |
|
(96,030 |
) |
|
(14,144 |
) |
| Net impairment losses on financial and contract assets |
(331 |
) |
|
(1,107 |
) |
|
(163 |
) |
|
(736 |
) |
|
(2,097 |
) |
|
(309 |
) |
| Other income/(loss) - net |
259 |
|
|
3,819 |
|
|
562 |
|
|
11,813 |
|
|
(513 |
) |
|
(75 |
) |
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| Operating expenses |
(119,956 |
) |
|
(128,842 |
) |
|
(18,977 |
) |
|
(321,279 |
) |
|
(355,609 |
) |
|
(52,376 |
) |
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| Operating loss |
(84,010 |
) |
|
(59,210 |
) |
|
(8,722 |
) |
|
(222,109 |
) |
|
(179,516 |
) |
|
(26,440 |
) |
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| Finance income |
26 |
|
|
12,772 |
|
|
1,881 |
|
|
438 |
|
|
11,062 |
|
|
1,629 |
|
| Finance costs |
(2,134 |
) |
|
(1,560 |
) |
|
(230 |
) |
|
(3,603 |
) |
|
(3,997 |
) |
|
(589 |
) |
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| Finance (costs)/income - net |
(2,108 |
) |
|
11,212 |
|
|
1,651 |
|
|
(3,165 |
) |
|
7,065 |
|
|
1,040 |
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| Fair value loss of financial instruments with preferred
rights |
(187,955 |
) |
|
- |
|
|
- |
|
|
(315,962 |
) |
|
(2,823,370 |
) |
|
(415,837 |
) |
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| Loss before income tax |
(274,073 |
) |
|
(47,998 |
) |
|
(7,071 |
) |
|
(541,236 |
) |
|
(2,995,821 |
) |
|
(441,237 |
) |
| Income tax expense |
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
|
- |
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| Loss for the period |
(274,073 |
) |
|
(47,998 |
) |
|
(7,071 |
) |
|
(541,236 |
) |
|
(2,995,821 |
) |
|
(441,237 |
) |
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| Loss attributable to: |
|
|
|
|
|
|
|
| Owners of the Company |
(274,073 |
) |
|
(47,998 |
) |
|
(7,071 |
) |
|
(541,236 |
) |
|
(2,995,821 |
) |
|
(441,237 |
) |
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| Loss per share |
RMB |
|
|
RMB |
|
|
USD |
|
|
RMB |
|
|
RMB |
|
|
USD |
|
| -Basic and diluted |
(2.15 |
) |
|
(0.11 |
) |
|
(0.02 |
) |
|
(4.35 |
) |
|
(12.02 |
) |
|
(1.77 |
) |
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| Loss per ADS |
|
|
|
|
|
|
|
| -Basic and diluted |
|
(0.53 |
) |
|
(0.08 |
) |
|
|
(60.10 |
) |
|
(8.85 |
) |
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| Shares used in loss
per ordinary share computation: |
|
|
|
|
|
|
|
| -Basic and diluted |
127,274,280 |
|
|
454,231,486 |
|
|
454,231,486 |
|
|
124,286,433 |
|
|
249,230,922 |
|
|
249,230,922 |
|
| ADS used in loss per
ADS computation: |
|
|
|
|
|
|
|
| -Basic and diluted |
|
90,846,297 |
|
|
90,846,297 |
|
|
|
49,846,184 |
|
|
49,846,184 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
GENETRON HOLDINGS LIMITEDUNAUDITED
NON-IFRS FINANCIAL MEASURE
| |
|
|
|
|
|
| |
For the
three months ended |
For the nine months ended |
| |
| |
|
|
|
|
| |
September 30,
2019 |
September 30, 2020 |
September 30,
2019 |
September 30, 2020 |
| |
RMB’000 |
RMB’000 |
US$’000 |
RMB’000 |
RMB’000 |
US$’000 |
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| Loss for the
period |
(274,073 |
) |
|
(47,998 |
) |
|
(7,071 |
) |
|
(541,236 |
) |
|
(2,995,821 |
) |
|
(441,237 |
) |
| Adjustments: |
|
|
|
|
|
|
| Share-based compensation |
10,755 |
|
|
4,268 |
|
|
629 |
|
|
31,494 |
|
|
19,222 |
|
|
2,831 |
|
| Fair value loss of financial instruments with preferred
rights |
187,955 |
|
|
- |
|
|
- |
|
|
315,962 |
|
|
2,823,370 |
|
|
415,837 |
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| Non-IFRS
Loss |
(75,363 |
) |
|
(43,730 |
) |
|
(6,442 |
) |
|
(193,780 |
) |
|
(153,229 |
) |
|
(22,569 |
) |
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| Attributable to: |
|
|
|
|
|
|
| Owners of the Company |
(75,363 |
) |
|
(43,730 |
) |
|
(6,442 |
) |
|
(193,780 |
) |
|
(153,229 |
) |
|
(22,569 |
) |
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
Non-IFRS loss per share |
RMB |
|
|
RMB |
|
|
USD |
|
|
RMB |
|
|
|
RMB |
|
|
USD |
|
| -Basic and diluted |
(0.59 |
) |
|
(0.10 |
) |
|
(0.01 |
) |
|
(1.56 |
) |
|
(0.61 |
) |
|
(0.09 |
) |
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| Non-IFRS loss per
ADS(5 ordinary shares equal to 1 ADS) |
|
|
|
|
|
|
| -Basic and diluted |
|
(0.48 |
) |
|
(0.07 |
) |
|
|
(3.07 |
) |
|
(0.45 |
) |
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| Shares used in
non-IFRS loss per ordinary share computation: |
|
|
|
|
|
|
| -Basic and diluted |
127,274,280 |
|
|
454,231,486 |
|
|
454,231,486 |
|
|
124,286,433 |
|
|
249,230,922 |
|
|
249,230,922 |
|
| |
|
|
|
|
|
|
| ADS used in non-IFRS
loss per ADS computation: |
|
|
|
|
|
|
| -Basic and diluted |
|
90,846,297 |
|
|
90,846,297 |
|
|
|
49,846,184 |
|
|
49,846,184 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
GENETRON HOLDINGS LIMITEDUNAUDITED
REVENUE AND SEGMENT INFORMATION
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
Diagnosis andmonitoring |
|
Diagnosis andmonitoring |
|
Developmentservices |
|
Total |
| - provision ofLDT services |
- sale of IVDproducts |
| |
RMB’000 |
|
RMB’000 |
|
RMB’000 |
|
RMB’000 |
| |
|
|
|
|
|
|
|
| Three months ended September 30,
2019 |
|
|
|
|
|
|
|
Revenue |
60,542 |
|
9,490 |
|
11,312 |
|
|
81,344 |
| Segment profit/(loss) |
34,605 |
|
2,707 |
|
(1,366 |
) |
|
35,946 |
| |
|
|
|
|
|
|
|
| Three months ended September 30,
2020 |
|
|
|
|
|
|
| Revenue |
71,406 |
|
30,110 |
|
10,447 |
|
|
111,963 |
| Segment profit |
49,212 |
|
18,439 |
|
1,981 |
|
|
69,632 |
| |
|
|
|
|
|
|
|
| Nine months ended September 30,
2019 |
|
|
|
|
|
|
| Revenue |
169,285 |
|
14,434 |
|
36,766 |
|
|
220,485 |
| Segment profit/(loss) |
101,533 |
|
4,576 |
|
(6,939 |
) |
|
99,170 |
| |
|
|
|
|
|
|
|
| Nine months ended September 30,
2020 |
|
|
|
|
|
|
| Revenue |
194,754 |
|
67,468 |
|
28,319 |
|
|
290,541 |
| Segment profit |
130,961 |
|
43,827 |
|
1,305 |
|
|
176,093 |
| |
|
|
|
|
|
|
|
|
GENETRON HOLDINGS LIMITEDUNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS
|
|
As at
December
31,2019 |
As at September
30,2020 |
|
|
RMB’000 |
|
|
RMB’000 |
|
|
US$’000 |
|
| ASSETS |
|
|
|
|
|
|
|
|
| Non-current assets |
|
|
|
|
|
|
|
|
| Property, plant and equipment |
83,013 |
|
|
73,500 |
|
|
10,825 |
|
| Right-of-use assets |
43,182 |
|
|
57,204 |
|
|
8,425 |
|
| Intangible assets |
5,482 |
|
|
9,453 |
|
|
1,392 |
|
| Prepayments |
12,679 |
|
|
11,975 |
|
|
1,765 |
|
| |
|
|
|
|
|
|
|
|
| Total non-current assets |
144,356 |
|
|
152,132 |
|
|
22,407 |
|
| |
|
|
|
|
|
|
|
|
| Current assets |
|
|
|
|
|
|
|
|
| Inventories |
17,896 |
|
|
22,972 |
|
|
3,383 |
|
| Contract assets |
1,020 |
|
|
1,698 |
|
|
250 |
|
| Other current assets |
43,711 |
|
|
40,494 |
|
|
5,965 |
|
| Trade receivables |
83,757 |
|
|
128,013 |
|
|
18,854 |
|
| Other receivables and prepayments |
19,526 |
|
|
33,011 |
|
|
4,862 |
|
| Amounts due from related parties |
1,064 |
|
|
72 |
|
|
11 |
|
| Financial assets at fair value through profit or loss |
122,224 |
|
|
233,534 |
|
|
34,396 |
|
| Cash and cash equivalents |
139,954 |
|
|
1,635,000 |
|
|
240,809 |
|
| |
|
|
|
|
|
|
|
|
| Total current assets |
429,152 |
|
|
2,094,794 |
|
|
308,530 |
|
| |
|
|
|
|
|
|
|
|
| Total assets |
573,508 |
|
|
2,246,926 |
|
|
330,937 |
|
| |
|
|
|
|
|
|
|
|
GENETRON HOLDINGS LIMITEDUNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS
（CONTINUED)
| |
As
at
December
31,2019 |
As
at September
30,202 |
| |
RMB’000 |
RMB’000 |
US$’000 |
| |
|
|
|
| LIABILITIES |
|
|
|
| Non-current liabilities |
|
|
|
| Financial
instruments with preferred rights |
2,106,334 |
|
|
- |
|
|
- |
|
| Borrowings |
3,643 |
|
|
5,921 |
|
|
872 |
|
| Lease liabilities |
29,124 |
|
|
40,090 |
|
|
5,905 |
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| Total non-current liabilities |
2,139,101 |
|
|
46,011 |
|
|
6,777 |
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| Current liabilities |
|
|
|
| Trade payables |
49,955 |
|
|
26,595 |
|
|
3,917 |
|
| Contract liabilities |
18,189 |
|
|
6,132 |
|
|
903 |
|
| Other payables and accruals |
109,683 |
|
|
263,576 |
|
|
38,821 |
|
| Amounts due to related parties |
34 |
|
|
- |
|
|
- |
|
| Borrowings |
19,514 |
|
|
53,097 |
|
|
7,820 |
|
| Lease liabilities |
15,363 |
|
|
15,459 |
|
|
2,277 |
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| Total current liabilities |
212,738 |
|
|
364,859 |
|
|
53,738 |
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| Total liabilities |
2,351,839 |
|
|
410,870 |
|
|
60,515 |
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| Net (liabilities)/assets |
(1,778,331 |
) |
|
1,836,056 |
|
|
270,422 |
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| SHAREHOLDERS’ (DEFICIT)/EQUITY |
|
|
|
| (Deficit)/equity attributable to owners of the
Company |
|
|
|
|
|
| Share capital |
17 |
|
|
59 |
|
|
9 |
|
| Share premium |
- |
|
|
6,657,562 |
|
|
980,553 |
|
| Treasury shares |
(3,578 |
) |
|
- |
|
|
- |
|
| Other reserves |
69,207 |
|
|
18,233 |
|
|
2,685 |
|
| Accumulated losses |
(1,843,977 |
) |
|
(4,839,798 |
) |
|
(712,825 |
) |
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
|
Total shareholders’ (deficit)/equity |
(1,778,331 |
) |
|
1,836,056 |
|
|
270,422 |
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
| |
|
|
|
Genetron (NASDAQ:GTH)
Historical Stock Chart
From May 2024 to Jun 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Jun 2023 to Jun 2024
